Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadofaragene Firadenovec in Low-grade Upper Tract Urothelial Carcinoma
NCT06668493Phase 2Recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nadofaragene firadenovec in upper tract urothelial carcinoma (UTUC), sponsored by Ferring Pharmaceuticals. Primary endpoints: Number of treatment-emergent adverse events up to 30 months and Complete response up to 6 months. Started Jun 2025; status: recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06668493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668493.